One potential target for a vaccine strategy is tyrosinase (Tyr), a prototypical melanocytic differentiation antigen that is expressed homogenously by most melanoma specimens [9-11] and which elicits spontaneous CD8+ T cell responses [12-14]. This evidence concerns the gene TYR and melanoma.